Clinuvel Pharmaceuticals (ASX:CUV) sign CEO for three more years

Clinuvel Pharmaceuticals (ASX:CUV) sign CEO for three more years

 

Shares in Clinuvel Pharmaceuticals (ASX:CUV) rose today after it reported that its CEO Philippe Wolgen will stay with the company for three more years.

As its long-serving key executive, Dr Wolgen has steered the Company since its restructure in 2005 to its current successful position.

Clinuvel’s Head of Remuneration Committee Mr Willem Blijdorp says “Amongst its international peers, CLINUVEL ranks near the median value of total annual remuneration awarded to its CEO.”
 
Shares in Clinuvel Pharmaceuticals (ASX:CUV) are trading 2.1 per cent lower at $25.48.
Copyright 2019 – Finance News Network


Source: Finance News Network

Share this post